Ticker Details
Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
IPO Date:	May 28, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$44.59B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.77 | 2.19%
Avg Daily Range (30 D):	$5.78 | 1.69%
Avg Daily Range (90 D):	$6.65 | 1.64%

Institutional Daily Volume
Avg Daily Volume:	.56M
Avg Daily Volume (30 D):	1.37M
Avg Daily Volume (90 D):	1.11M

Trade Size
Avg Trade Size (Sh.):	75
Avg Trade Size (Sh.) (30 D):	35
Avg Trade Size (Sh.) (90 D):	33

Institutional Trades
Total Institutional Trades:	10,834
Avg Institutional Trade:	$7.97M
Avg Institutional Trade (30 D):	$24.83M
Avg Institutional Trade (90 D):	$42.5M
Avg Institutional Trade Volume:	.05M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$14.31M
Avg Closing Trade (30 D):	$65.95M
Avg Closing Trade (90 D):	$84.88M
Avg Closing Volume:	85.32K

News

Jan 21, 2026 @ 3:54 PM Amyloidosis Therapeutic Market to Worth Over US$ 6... Source: Astute Analytica

Jan 12, 2026 @ 6:33 PM Alnylam Lays Out 2030 Vision, Bets On TTR Leadersh... Source: Vandana Singh

Jan 7, 2026 @ 10:00 AM Scenic Biotech Enters License and Research Agreeme... Source: Unknown

Jan 2, 2026 @ 8:13 AM This AI Infrastructure Stock Is 'Most Likely' To B... Source: Vishaal Sanjay

Dec 13, 2025 @ 1:00 AM Annual Changes to the Nasdaq-100 Index® Source: Nasdaq

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.39	$.84	$2.39
Diluted EPS	$2.33	$.82	$2.33
Revenue	$3.71B	$1.1B	$3.71B
Gross Profit	$3.04B	$829.31M	$3.04B
Net Income / Loss	$313.75M	$111.54M	$313.75M
Operating Income / Loss	$501.58M	$131.72M	$501.58M
Cost of Revenue	$677.17M	$267.72M	$677.17M
Net Cash Flow	$690.16M	$166.01M	$690.16M
PE Ratio	142.85